Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.25.

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, January 23rd. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $7.00 price objective on shares of Esperion Therapeutics in a report on Thursday, January 23rd.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds have recently bought and sold shares of the company. Traphagen Investment Advisors LLC purchased a new stake in Esperion Therapeutics during the third quarter worth about $27,000. Versor Investments LP purchased a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $44,000. SJS Investment Consulting Inc. acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $55,000. Boomfish Wealth Group LLC lifted its holdings in Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,102 shares in the last quarter. Finally, Summit Wealth Group LLC purchased a new position in Esperion Therapeutics in the 3rd quarter valued at approximately $66,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $1.89 on Thursday. The stock’s fifty day moving average is $2.36 and its two-hundred day moving average is $2.14. The firm has a market capitalization of $372.41 million, a P/E ratio of -2.95 and a beta of 1.01. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $51.63 million for the quarter, compared to analysts’ expectations of $55.44 million. During the same quarter last year, the firm posted ($0.37) earnings per share. As a group, sell-side analysts forecast that Esperion Therapeutics will post -0.28 EPS for the current year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.